Latest News
Select the category
Director Dealing
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
Share Option Exercise
Scancell initiates new arm (Cohort 4) in SCOPE Phase 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+
Director Dealing
Partnership with NHS Cancer Vaccine Launch Pad Enabling Fast-Tracked Access for Melanoma Patients
No results found.
Regulatory News Archive
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.